Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
72°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Eli Lilly
(NY:
LLY
)
908.48
-33.12 (-3.52%)
Streaming Delayed Price
Updated: 3:34 PM EDT, Jul 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Eli Lilly
< Previous
1
2
...
23
24
25
26
27
28
29
30
31
...
98
99
Next >
7 Must-Buy Pharma Stocks Amid the Weight Loss Drug Revolution
February 14, 2024
Obesity drug sales boomed in 2023 and will continue in 2024. That could make these weight loss stocks even more attractive.
Via
InvestorPlace
Nearly Half Of S&P 500 Stocks Trade Below 50-Day Moving Average: Which One Is The Cheapest?
February 14, 2024
Nearly half of S&P 500 stocks are below 50-day moving average, indicating poor market breadth. Only top 5 companies shielded from bearish pressures.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
What's Going On With Eli Lilly Stock Wednesday?
February 14, 2024
Eli Lilly's shares surge 25% YTD to $700 billion enterprise value. Mounjaro and Zepbound drive growth with tirzepatide. BMO Capital projects $12.78 billion FY2024 tirzepatide revenues.
Via
Benzinga
3 Perfect Stocks to Buy This Valentine's Day
February 14, 2024
These stocks have sweet long-term prospects.
Via
The Motley Fool
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $6,000 Today
February 13, 2024
Via
Benzinga
This Unstoppable Growth Stock Just Announced More Good News: Is It a Buy?
February 12, 2024
The drugmaker continues to impress investors.
Via
The Motley Fool
Why Shares of Eli Lilly Popped This Week
February 09, 2024
The pharmaceutical giant is gaining momentum, and investors are excited.
Via
The Motley Fool
Amgen Takes Aim at Novo Nordisk and Eli Lilly, but Is the Stock a Buy?
February 14, 2024
It faces both clinical and competitive barriers, but they might not matter.
Via
The Motley Fool
Kerrisdale Capital Slams Altimmune (ALT) Stock in New Short Report
February 13, 2024
Kerrisdale Capital has released a short report, making clear why it is betting against ALT stock. Here's why Altimmune is likely in trouble.
Via
InvestorPlace
Altimmune Stock Sinks As Kerrisdale Capital Announces Short Position: 'Obvious Dead End'
February 13, 2024
Altimmune shares are trading lower Tuesday after short-selling investment firm Kerrisdale Capital published a new research report on the stock and announced a short position
Via
Benzinga
The S&P 500's 3 best 10-year performers are all in this industry
February 13, 2024
Given the critical role semiconductors play in the global economy, it’s no surprise that chipmakers have hauled in some serious profits over the past decade.
Via
MarketBeat
Topics
Economy
Stocks
Exposures
Economy
US Equities
Move Aside, Eli Lilly and Novo Nordisk. Wall Street Thinks This Stock Will Be a Bigger Winner Over the Next 12 Months.
February 13, 2024
There's more for investors to get excited about in the biopharma world than just weight-loss drugs.
Via
The Motley Fool
Is Eli Lilly Stock a Buy Now?
February 09, 2024
Eli Lilly's valuation is approaching $700 billion.
Via
The Motley Fool
Jim Cramer Warns Weight Loss Drugs Ozempic, Wegovy And Others Could Impact Food Stocks: 'That Day Will Come'
February 13, 2024
Jim Cramer, the host of CNBC's "Mad Money," has issued a warning to investors about the potential impact of weight loss drugs on the food and beverage industry.
Via
Benzinga
A Look At Pharma ETFs After Q4 Earnings
February 12, 2024
The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth.
Via
Talk Markets
Topics
ETFs
Eli Lilly's Weight Loss Drug Tripeptide Is Expanding Market Share, Analyst Outlines What Lies Ahead
February 12, 2024
Track Eli Lilly's tripeptide success. Weekly updates on Mounjaro and Zepbound prescriptions in the GLP-1 category. Analyst predicts $12.78 billion in fiscal year 2024 tripeptide revenues.
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
February 12, 2024
Via
Benzinga
2 Value Stocks With Monster Yields
February 12, 2024
These two low-priced large-cap stocks sport ginormous yields.
Via
The Motley Fool
Novo Nordisk, Eli Lilly Stride To Boost Supply Shortage For Newly Found Holy Grail Of Miraculous Weight Loss Drugs
February 12, 2024
Challenges and updates in the weight loss drug market, as Novo Nordisk and Eli Lilly address supply shortages for Wegovy and Mounjaro. Strategies to meet the increasing demand and potential market...
Via
Benzinga
Could Eli Lilly's Zepbound Become the World's Best-Selling Drug?
February 12, 2024
Everyone is excited about Zepbound, from patients to investors...
Via
The Motley Fool
Novo Nordisk Is Scaling a Barrier to Growth. Should You Buy Its Stock Now?
February 11, 2024
Even more revenue is on the way from additional sales of Wegovy.
Via
The Motley Fool
Could This Warren Buffett Advice Help You Become a Millionaire?
February 11, 2024
Both experienced and new investors may benefit from this investment...
Via
The Motley Fool
Eli Lilly Just Succeeded Where Others Failed, but Does It Matter for the Stock?
February 10, 2024
Potentially adding billions of dollars in revenue might move the needle for the pharmaceutical giant, but that could take years.
Via
The Motley Fool
MarketBeat Week in Review – 2/5 - 2/9
February 10, 2024
The markets continue to rise as investors come to grips with higher interest rates, but next week's inflation data may cool down the bullish momentum
Via
MarketBeat
Topics
Artificial Intelligence
Economy
Exposures
Artificial Intelligence
Interest Rates
3 Stocks That Could Trounce the Market in 2024
February 10, 2024
These stocks appear to have what it takes to beat the market this year.
Via
The Motley Fool
S&P 500 Hits 5,000, Magnificent 7 Tops $13 Trillion, Commercial Real Estate Cracks Emerge: The Week In The Markets
February 09, 2024
The S&P 500 index surged past 5,000, led by tech giants. Tesla falls to ninth in market cap, Novo Nordisk disrupts food industry, Ackman targets retail investors.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
3 Stocks to Sell Immediately Before the Bubble Bursts: February 2024
February 09, 2024
These three high-flying stocks to sell are set for a major decline when the stock market bubble pops. It's time to dump them.
Via
InvestorPlace
Is Tesla Still A Magnificent 7 Stock? EV Maker Could Get Bumped By These Companies
February 09, 2024
Tesla, relegated from seventh to ninth on the mega-cap leaderboard, can give way to other companies that are more 'magnificent.'
Via
Benzinga
SPDR ETF Report For Thursday, February 8
February 09, 2024
In this video, Ira Epstein reviews the day's trading in various SPDR-ETF markets for the trading day just ended, Thursday, February 8
Via
Talk Markets
Topics
ETFs
Jim Cramer Says Investors Should Look Beyond Apple, Meta And Other Magnificent 7 Stocks: 'You Might Be Missing Out On Some Huge Gains'
February 08, 2024
Jim Cramer, the host of CNBC's "Mad Money," has suggested that investors should look beyond the Magnificent Seven tech stocks for potential high-yield investments.
Via
Benzinga
< Previous
1
2
...
23
24
25
26
27
28
29
30
31
...
98
99
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.